Table 3.
Baseline and final non-mineral-related end points
| Characteristics | Cholecalciferol |
Doxercalciferol |
Between-Treatment Group Pa | ||||
|---|---|---|---|---|---|---|---|
| Baseline (n = 22) | Final (n = 20) | Pre-Post P | Baseline (n = 25) | Final (n = 20) | Pre-Post P | ||
| Home systolic BP | 145 ± 20 | 128 ± 34 | 0.17 | 142 ± 15 | 120 ± 47 | 0.07 | 0.48 |
| Home diastolic BP | 75 ± 14 | 64 ± 12 | 0.11 | 75 ± 11 | 67 ± 26 | 0.25 | 0.97 |
| Standardized systolic BP | 139 ± 17 | 140 ± 20 | 0.42 | 141 ± 19 | 137 ± 20 | 0.63 | 0.29 |
| Standardized diastolic BP | 74 ± 11 | 73 ± 16 | 0.81 | 77 ± 13 | 74 ± 15 | 0.43 | 0.26 |
| Urine albumin/creatinine ratio, μg/mg | 964 ± 1059 | 669 ± 667 | 0.36 | 755 ± 1230 | 438 ± 860 | 0.1 | 0.47 |
a
By repeated-measures two-way ANOVA with visit (baseline and end point), drug, and their interaction as factors.